| Antisense oligonucleotides: an emerging area in drug discovery and development K Dhuri, C Bechtold, E Quijano, H Pham, A Gupta, A Vikram, R Bahal Journal of clinical medicine 9 (6), 2004, 2020 | 312 | 2020 |
| Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy A Wahane, A Waghmode, A Kapphahn, K Dhuri, A Gupta, R Bahal Molecules 25 (12), 2866, 2020 | 156 | 2020 |
| Nanoparticle delivered anti-miR-141-3p for stroke therapy K Dhuri, RN Vyas, L Blumenfeld, R Verma, R Bahal Cells 10 (5), 1011, 2021 | 30 | 2021 |
| Therapeutic potential of chemically modified, synthetic, triplex peptide nucleic acid–based oncomir inhibitors for cancer therapy K Dhuri, RR Gaddam, A Vikram, FJ Slack, R Bahal Cancer research 81 (22), 5613-5624, 2021 | 19 | 2021 |
| Microbiota-governed microRNA-204 impairs endothelial function and blood pressure decline during inactivity in db/db mice RR Gaddam, VP Jacobsen, YR Kim, M Gabani, JS Jacobs, K Dhuri, ... Scientific reports 10 (1), 10065, 2020 | 15 | 2020 |
| γ peptide nucleic acid-based miR-122 inhibition rescues vascular endothelial dysfunction in mice fed a high-fat diet RR Gaddam, K Dhuri, YR Kim, JS Jacobs, V Kumar, Q Li, K Irani, R Bahal, ... Journal of medicinal chemistry 65 (4), 3332-3342, 2022 | 9 | 2022 |
| An Emerging Area in Drug Discovery and Development., 2020, 9, 2004 K Dhuri, C Bechtold, E Quijano, H Pham, A Gupta, A Vikram, ... DOI: https://doi. org/10.3390/jcm9062004. PMID: https://www. ncbi. nlm. nih …, 0 | 6 | |
| Simultaneous targeting of multiple oncomiRs with phosphorothioate or PNA-based anti-miRs in lymphoma cell lines K Dhuri, SP Pradeep, J Shi, E Anastasiadou, FJ Slack, A Gupta, X Zhong, ... Pharmaceutical research 39 (11), 2709-2720, 2022 | 5 | 2022 |
| Serine-γPNA, Invader probes, and chimeras thereof: Three probe chemistries that enable sequence-unrestricted recognition of double-stranded DNA RG Emehiser, K Dhuri, C Shepard, S Karmakar, R Bahal, PJ Hrdlicka Organic & biomolecular chemistry 20 (44), 8714-8724, 2022 | 2 | 2022 |
| Head-to-head comparison of in vitro and in vivo efficacy of pHLIP-conjugated anti-seed gamma peptide nucleic acids K Dhuri, T Duran, B Chaudhuri, FJ Slack, A Vikram, PM Glazer, R Bahal Cell Reports Physical Science 4 (10), 2023 | 1 | 2023 |
| Abstract WP315: Pharmacological Validation of Advanced Gamma Peptide Nucleic Acid (PNA) Based miR Inhibitors for Ischemic Stroke Treatment SK Yadav, D Gamiotea Turro, V Patel, K Dhuri, R Bahal, R Verma Stroke 55 (Suppl_1), AWP315-AWP315, 2024 | | 2024 |
| Methods and compositions comprising therapeutic gamma peptide nucleic acid-based molecules A Vikram, K Irani, RR Gaddam, R Bahal, K Dhuri US Patent App. 18/165,809, 2023 | | 2023 |
| Next Generation Oncogenic MicroRNAs Inhibitors for Cancer Therapeutics A Gupta, F Iqbal, K Dhuri, R Bahal American Journal of Pharmaceutical Education 87 (8), 100156, 2023 | | 2023 |
| MicroRNA-122 Targeting With Gamma Peptide Nucleic Acid Inhibitor Improves Vascular Endothelial Dysfunction In Pre-diabetic Mice. RR Gaddam, K Dhuri, YR Kim, JS Jacobs, V Kumar, Q Li, K Irani, R Bahal, ... CIRCULATION RESEARCH 131, 2022 | | 2022 |
| Abstract P3013: MicroRNA-122 Targeting With Gamma Peptide Nucleic Acid Inhibitor Improves Vascular Endothelial Dysfunction In Pre-diabetic Mice. RR Gaddam, K Dhuri, YR Kim, JS Jacobs, V Kumar, Q Li, K Irani, R Bahal, ... Circulation research 131 (Suppl_1), AP3013-AP3013, 2022 | | 2022 |
| Abstract P774: Therapeutic Efficacy of Next Generation Anti-miR-141-3p for Ischemic Stroke K Dhuri, L Blumenfeld, R Bahal, R Verma Stroke 52 (Suppl_1), AP774-AP774, 2021 | | 2021 |
